CytoSorbents, Inc.

408 articles about CytoSorbents, Inc.

• CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

  12/20/2021

  CytoSorbents Corporation announces the publication of results from the Company's U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine.

• CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results

  11/4/2021

    CytoSorbents Corporation reports full financial and operating results for the quarter ended September 30, 2021.

• First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

  10/14/2021

  CytoSorbents Corporation announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR™ Antithrombotic Removal System for intraoperative removal of ticagrelor during cardiothoracic surgery. 

• CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

  10/12/2021

  Preliminary third quarter 2021 total revenue was $9.7 million, including product sales of $8.9 million. Preliminary core non-COVID-19 product sales increased 4% Y-Y to approximately $7.8 million.

• CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

  9/14/2021

  Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients

• CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

  9/10/2021

  CytoSorbents Corporation announces the filing of an Investigational Device Exemption (IDE) application to gain FDA approval to conduct the clinical study, "Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants (STAR-D),"

• Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

  9/1/2021

  CytoSorbents Corporation announced that topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry were presented at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) in Brussels, Belgium yesterday.

• CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

  8/30/2021

  CytoSorbents Corporation and Aferetica srl announce the commercial launch of Aferetica's PerLife™ ex vivo organ perfusion system for kidney and liver transplant and CytoSorbents' PerSorb™ adsorber, based on the CytoSorbents ECOS-300CY™ sorbent technology to remove inflammatory mediators during ex vivo organ perfusion, at the European Society of Organ Transplantation Congress in Milan, Italy from August 29 – September 1, 2021.

• Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

  8/12/2021

  CytoSorbents Corporation announced that the Company has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration (FDA).

• CytoSorbents to Report Second Quarter 2021 Operating and Financial Results

  7/19/2021

  CytoSorbents Corporation a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, will report second quarter 2021 operating and financial results after the market close on August 3, 2021.

• CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery

  7/6/2021

  CytoSorbents Corporation announces the full approval of its Investigational Device Exemption application to conduct the pivotal STAR-T double-blind, randomized, controlled trial in the United States to support FDA regulatory clearance.

• CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

  6/1/2021

  Terri Anne Powers, IRC, experienced financial and communications professional, to strengthen and expand relationships with the investment and broader stakeholder community by building best-in-class investor relations and corporate communications function

• CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

  5/27/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb®  blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021.

• CytoSorb® Registered and Commercially Available in Singapore

  5/25/2021

  CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical

• CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit

  5/19/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb®  blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the UBS Global Conference

• CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

  5/11/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb ® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a contract

• U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

  4/19/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader whose flagship E.U. approved CytoSorb ® blood purification technology is intended to treat deadly conditions in critically-ill and cardiac surgery patients, announces that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its investigational device exemption application

• CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

  3/29/2021

  CytoSorbents Corporation announces the lease of its new global headquarters in Princeton, NJ. On March, 26, 2021, the company entered into a new agreement with National Business Parks to lease approximately 48,500 square feet located at 305 College Road East at Princeton Forrestal Village in Princeton, New Jersey.

• CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/12/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb®  blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Oppenheimer 31 st Annual Healthcare Conference.

• B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

  3/2/2021

  Joint marketing of CytoSorb® with B. Braun's newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.